SI4308114T1 - Zaviralci c5ar1 za zdravljenje preobčutljivostnih reakcij na taksan - Google Patents
Zaviralci c5ar1 za zdravljenje preobčutljivostnih reakcij na taksanInfo
- Publication number
- SI4308114T1 SI4308114T1 SI202230262T SI202230262T SI4308114T1 SI 4308114 T1 SI4308114 T1 SI 4308114T1 SI 202230262 T SI202230262 T SI 202230262T SI 202230262 T SI202230262 T SI 202230262T SI 4308114 T1 SI4308114 T1 SI 4308114T1
- Authority
- SI
- Slovenia
- Prior art keywords
- c5ar1
- taxanes
- inhibitors
- hypersensitivity reactions
- treating hypersensitivity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21163292.2A EP4059497A1 (en) | 2021-03-17 | 2021-03-17 | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| EP21217382 | 2021-12-23 | ||
| EP22716203.9A EP4308114B1 (en) | 2021-03-17 | 2022-03-17 | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| PCT/EP2022/057007 WO2022195017A1 (en) | 2021-03-17 | 2022-03-17 | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI4308114T1 true SI4308114T1 (sl) | 2026-05-29 |
Family
ID=81307212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI202230262T SI4308114T1 (sl) | 2021-03-17 | 2022-03-17 | Zaviralci c5ar1 za zdravljenje preobčutljivostnih reakcij na taksan |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240180888A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4308114B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024512472A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023018826A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3212816A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4308114T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4308114T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20260351T1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305727A (cg-RX-API-DMAC7.html) |
| LT (1) | LT4308114T (cg-RX-API-DMAC7.html) |
| PL (1) | PL4308114T3 (cg-RX-API-DMAC7.html) |
| RS (1) | RS67911B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI4308114T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202600118T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022195017A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202543631A (zh) * | 2024-03-14 | 2025-11-16 | 美商凡況生化公司 | 嗒嗪酮c5ar1拮抗劑及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002500667A (ja) * | 1997-05-27 | 2002-01-08 | ベーカー ノートン ファーマシューティカルズ インコーポレイテッド | 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物 |
| DE69828615T2 (de) * | 1997-10-31 | 2005-12-01 | Walter Reed Army Institute Of Research | Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten |
| RU2002113659A (ru) * | 1999-10-27 | 2004-01-27 | Бейкер Нортон Фармасьютикалз, Инк. (Us) | Способ и композиции для перорального введения таксанов больным людям |
| JP5374157B2 (ja) * | 2005-11-24 | 2013-12-25 | ドムペ・ファ.ル.マ・ソチエタ・ペル・アツィオーニ | (r)−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物 |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
-
2022
- 2022-03-17 WO PCT/EP2022/057007 patent/WO2022195017A1/en not_active Ceased
- 2022-03-17 LT LTEPPCT/EP2022/057007T patent/LT4308114T/lt unknown
- 2022-03-17 BR BR112023018826A patent/BR112023018826A2/pt unknown
- 2022-03-17 HR HRP20260351TT patent/HRP20260351T1/hr unknown
- 2022-03-17 DK DK22716203.9T patent/DK4308114T3/da active
- 2022-03-17 JP JP2023556979A patent/JP2024512472A/ja active Pending
- 2022-03-17 SI SI202230262T patent/SI4308114T1/sl unknown
- 2022-03-17 RS RS20260336A patent/RS67911B1/sr unknown
- 2022-03-17 IL IL305727A patent/IL305727A/en unknown
- 2022-03-17 US US18/282,357 patent/US20240180888A1/en active Pending
- 2022-03-17 CA CA3212816A patent/CA3212816A1/en active Pending
- 2022-03-17 FI FIEP22716203.9T patent/FI4308114T3/fi active
- 2022-03-17 EP EP22716203.9A patent/EP4308114B1/en active Active
- 2022-03-17 SM SM20260118T patent/SMT202600118T1/it unknown
- 2022-03-17 PL PL22716203.9T patent/PL4308114T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240180888A1 (en) | 2024-06-06 |
| PL4308114T3 (pl) | 2026-05-04 |
| EP4308114B1 (en) | 2026-02-11 |
| RS67911B1 (sr) | 2026-04-30 |
| EP4308114A1 (en) | 2024-01-24 |
| WO2022195017A1 (en) | 2022-09-22 |
| FI4308114T3 (fi) | 2026-03-25 |
| DK4308114T3 (da) | 2026-03-23 |
| IL305727A (en) | 2023-11-01 |
| JP2024512472A (ja) | 2024-03-19 |
| LT4308114T (lt) | 2026-03-25 |
| CA3212816A1 (en) | 2022-09-22 |
| BR112023018826A2 (pt) | 2024-03-12 |
| HRP20260351T1 (hr) | 2026-04-24 |
| SMT202600118T1 (it) | 2026-05-12 |